B-Raf IN 17

B-Raf IN 17

• UNSPSC Description: B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of BRAFWT, VEGFR-2, and FGFR-1 in A375 cell line, with IC50 values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer[1].
• Target Antigen: FGFR; Raf; VEGFR
• Type: Reference compound
• Related Pathways: MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/b-raf-in-17.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=CC=C2NC(C3=CC=CC=C3)=NC2=C1)N/N=C4C(NC5=C/4C=C(C=C5)Br)=O
• Molecular Weight: 460.28
• References & Citations: [1]Allam RM, et al. Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma. Bioorg Chem. 2024 Feb 26;146:107243.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported